PAVmed (NASDAQ:PAVM) Shares Down 4.4% – Should You Sell?

PAVmed Inc. (NASDAQ:PAVM) shares traded down 4.4% on Monday . The stock traded as low as $0.61 and last traded at $0.64. 379,800 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 629,766 shares. The stock had previously closed at $0.67.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets reduced their target price on PAVmed from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th.

PAVmed Trading Down 4.4 %

The stock’s 50-day moving average is $0.90 and its 200-day moving average is $0.98. The stock has a market cap of $7.12 million, a price-to-earnings ratio of -0.15 and a beta of 0.70.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.